Reblozyl and Fall - a phase IV clinical study of FDA data

Summary:

Fall is reported as a side effect among people who take Reblozyl (luspatercept-aamt), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Vidaza, and have Myelodysplastic syndrome.

The phase IV clinical study analyzes which people have Fall when taking Reblozyl. It is created by eHealthMe based on reports of 1,304 people who have side effects when taking Reblozyl from the FDA, and is updated regularly.

What is Reblozyl?

Reblozyl has active ingredients of luspatercept-aamt. eHealthMe is studying from 1,305 Reblozyl users. Check the latest studies of Reblozyl.

What is Fall?

Fall is found to be associated with 3,232 drugs and 3,759 conditions by eHealthMe. Check the latest studies of Fall.

On Jul, 24, 2026

1,304 people reported to have side effects when taking Reblozyl.
Among them, 32 people (2.45%) have Fall.

Among these 32 people:

How long have people been on Reblozyl when they have Fall? *

What is the gender of people who have Fall when taking Reblozyl? *

female: 55.17 %
male: 44.83 %

What is the age of people who have Fall when taking Reblozyl? *

What are other drugs people take besides Reblozyl? *

What are other side effects people have besides Fall? *

Dizziness: 5 people, 15.62%
Loss Of Consciousness: 4 people, 12.50%
Weakness: 3 people, 9.38%
Rib Fracture: 3 people, 9.38%
Hip Fracture: 3 people, 9.38%
Head Injury: 3 people, 9.38%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 2 people, 6.25%
Haemoglobin Decreased: 2 people, 6.25%
Dyspnea (difficult or laboured breathing): 2 people, 6.25%
Cerebral Haemorrhage (bleeding within the brain): 2 people, 6.25%

What are the existing conditions these people have? *

Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 23 people, 71.88%
Red Blood Cell Count Decreased: 1 person, 3.12%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 3.12%
Primary Myelofibrosis (primary disorder of the bone marrow): 1 person, 3.12%
Pain: 1 person, 3.12%
Osteoporosis (bones weak and more likely to break): 1 person, 3.12%
High Blood Pressure: 1 person, 3.12%
Haemoglobin Decreased: 1 person, 3.12%
Fatigue (feeling of tiredness): 1 person, 3.12%
Depression: 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Reblozyl and have Fall?

- Check whether Fall is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Reblozyl:

Reblozyl (1,305 reports)

Fall treatments and more:

Fall (403,513 reports)

Browse all side effects of Reblozyl:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fall:

Fall (3,232 drugs)

Browse all the conditions that are associated with Fall:

Fall (3,759 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on luspatercept-aamt (the active ingredients of Reblozyl) and Reblozyl (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.